Cellosaurus logo
expasy logo

Cellosaurus U266B1 (CVCL_0566)

[Text version]
Cell line name U266B1
Synonyms U266-B1; U266 B1; U-266; U 266; U266; U266S; U266BL; U266 Bl; 266 Bl
Accession CVCL_0566
Resource Identification Initiative To cite this cell line use: U266B1 (RRID:CVCL_0566)
Comments Group: Hybridoma fusion partner cell line.
Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: LL-100 blood cancer cell line panel.
Part of: MD Anderson Cell Lines Project.
Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981).
Population: Caucasian.
Characteristics: Produces IgE lambda.
Doubling time: 108-144 hours (PubMed=4104421); ~55 hours (DSMZ=ACC-9).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Array-based CGH.
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck, Catherine.
Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
Cell type: B-cell; CL=CL_0000236.
Sequence variations
  • Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Lys601Asn (c.1803A>T); ClinVar=VCV000376285; Zygosity=Heterozygous (Cosmic-CLP=753615; DepMap=ACH-000626).
  • Mutation; HGNC; HGNC:7329; MSH6; Simple; p.Gly141Asp (c.422G>A); ClinVar=VCV001491786; Zygosity=Heterozygous (Cosmic-CLP=753615; DepMap=ACH-000626).
  • Mutation; HGNC; HGNC:11998; TP53; Simple; p.Ala161Thr (c.481G>A); ClinVar=VCV000161518; Zygosity=Homozygous (PubMed=1373872; PubMed=21173094; Cosmic-CLP=753615; DepMap=ACH-000626).
  • Mutation; HGNC; HGNC:12033; TRAF3; Simple; p.Lys550Leufs*3 (c.1648_1649insT); Zygosity=Homozygous (PubMed=17692805).
HLA typing Source: Direct_author_submission
Class I
HLA-AA*02:01,03
HLA-BB*07,40
HLA-CC*03:04,07

Source: PubMed=26589293
Class I
HLA-AA*02:01,03:01
HLA-BB*07:02,40:01
HLA-CC*03:04,07:02

Source: DSMZCellDive=ACC-9
Class I
HLA-AA*02:01:01;03:01:01
HLA-BB*07:02:01,40:01:02
HLA-CC*03:04:01,07:02:01
Class II
HLA-DPDPA1*01:03:01,01:03:01
DPB1*04:01:01,02:01:02
HLA-DQDQA1*01:02:01,05:01:01
DQB1*02:01:01,06:02:01
HLA-DRDRA*01:02:02,01:02:03
DRB1*03:01:01,15:01:01
Genome ancestry Source: PubMed=30894373

Origin% genome
African0
Native American0
East Asian, North2.78
East Asian, South0.29
South Asian0.45
European, North80.76
European, South15.72
Disease Plasma cell myeloma (NCIt: C3242)
Multiple myeloma (ORDO: Orphanet_29073)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_C833 (AF10)CVCL_J235 (FU-266)CVCL_4974 (SKO-007)
CVCL_0015 (U-266/70)CVCL_0016 (U-266/84)CVCL_GZ72 (U266/ADM)
CVCL_VJ36 (U266/BR)CVCL_T031 (U266/velR)CVCL_D5KP (U266B1-Fluc-EmGFP)
CVCL_D5KQ (U266B1-Fluc-Puro)CVCL_C828 (U266R)
Originate from same individual CVCL_JA36 ! U255
CVCL_W412 ! U268
Sex of cell Male
Age at sampling 53Y
Category Cancer cell line
STR profile Source(s): ATCC=TIB-196; CCRID; CLS=300259; Cosmic-CLP=753615; DSMZ=ACC-9; ECACC=85051003; PubMed=25877200; Technion Genomics Center

Markers:
AmelogeninX,Y
CSF1PO12,13
D1S165612,15
D2S44110,11
D2S133820,23
D3S135817
D5S81811,12
D6S104311,17
D7S82011,12
D8S117913
D10S124814
D12S39118
D13S31712
D16S53910
D18S5112,14
D19S43313,15
D21S1128,29
D22S104515,16
DYS39110
FGA18
Penta D10,13
Penta E10,12
TH015,7
TPOX8
vWA17

Run an STR similarity search on this cell line
Web pages https://www.keatslab.org/myeloma-cell-lines/hmcl-characteristics
https://tcpaportal.org/mclp/
Publications

PubMed=4097745; PMCID=PMC1712861
Nilsson K., Bennich H., Johansson S.G.O., Ponten J.
Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient.
Clin. Exp. Immunol. 7:477-489(1970)

PubMed=4104421; DOI=10.1002/ijc.2910070303
Nilsson K.
Characteristics of established myeloma and lymphoblastoid cell lines derived from an E myeloma patient: a comparative study.
Int. J. Cancer 7:380-396(1971)

PubMed=6350451; DOI=10.4049/jimmunol.131.3.1201
Abrams P.G., Knost J.A., Clarke G., Wilburn S., Oldham R.K., Foon K.A.
Determination of the optimal human cell lines for development of human hybridomas.
J. Immunol. 131:1201-1204(1983)

PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0
Drexler H.G., Gaedicke G., Minowada J.
Isoenzyme studies in human leukemia-lymphoma cell lines -- 1 carboxylic esterase.
Leuk. Res. 9:209-229(1985)

PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1
Drexler H.G., Gaedicke G., Minowada J.
Isoenzyme studies in human leukemia-lymphoma cell lines -- III Beta-hexosaminidase (E.C. 3.2.1.30).
Leuk. Res. 9:549-559(1985)

PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x
Drexler H.G., Gaedicke G., Minowada J.
Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid phosphatase.
Leuk. Res. 9:537-548(1985)

PubMed=2537114; DOI=10.1182/blood.V73.2.566.566
Duperray C., Klein B., Durie B.G.M., Zhang X., Jourdan M., Poncelet P., Favier F., Vincent C., Brochier J., Lenoir G.M., Bataille F.-R.
Phenotypic analysis of human myeloma cell lines.
Blood 73:566-572(1989)

PubMed=2140233; DOI=10.1111/j.1440-1827.1990.tb01549.x
Nakano A., Harada T., Morikawa S., Kato Y.
Expression of leukocyte common antigen (CD45) on various human leukemia/lymphoma cell lines.
Acta Pathol. Jpn. 40:107-115(1990)

PubMed=1720489; DOI=10.1016/0145-2126(91)90110-f
Suzuki A., Takahashi T., Okuno Y., Fukumoto M., Fukui H., Koishihara Y., Ohsugi Y., Ohno Y., Imura H.
Estimation of interleukin 6 production by reverse transcriptase-polymerase chain reaction in four human myeloma cell lines.
Leuk. Res. 15:1043-1050(1991)

PubMed=1373872
Mazars G.-R., Portier M., Zhang X.-G., Jourdan M., Bataille F.-R., Theillet C., Klein B.
Mutations of the p53 gene in human myeloma cell lines.
Oncogene 7:1015-1018(1992)

PubMed=1643757; DOI=10.1016/0090-1229(92)90205-3
Renz H., Or R., Domenico J., Leung D.Y.M., Gelfand E.W.
Reciprocal regulatory effects of IL-4 on cell growth and immunoglobulin production in Ig-secreting human B-cell lines.
Clin. Immunol. Immunopathol. 64:233-241(1992)

PubMed=8943038; DOI=10.1073/pnas.93.24.13931; PMCID=PMC19472
Bergsagel P.L., Chesi M., Nardini E., Brents L.A., Kirby S.L., Kuehl W.M.
Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma.
Proc. Natl. Acad. Sci. U.S.A. 93:13931-13936(1996)

PubMed=9685479; DOI=10.1093/nar/26.16.3651; PMCID=PMC147775
Hultdin M., Gronlund E., Norrback K.-F., Eriksson-Lindstrom E., Just T., Roos G.
Telomere analysis by fluorescence in situ hybridization and flow cytometry.
Nucleic Acids Res. 26:3651-3656(1998)

PubMed=10087940; DOI=10.1016/S0165-4608(98)00157-5
Kuipers J., Vaandrager J.W., Weghuis D.O., Pearson P.L., Scheres J., Lokhorst H.M., Clevers H.C., Bast B.J.E.G.
Fluorescence in situ hybridization analysis shows the frequent occurrence of 14q32.3 rearrangements with involvement of immunoglobulin switch regions in myeloma cell lines.
Cancer Genet. Cytogenet. 109:99-107(1999)

PubMed=10557056; DOI=10.1038/sj.leu.2401563
Yoshida S., Nakazawa N., Iida S., Hayami Y., Sato S., Wakita A., Shimizu S., Taniwaki M., Ueda R.
Detection of MUM1/IRF4-IgH fusion in multiple myeloma.
Leukemia 13:1812-1816(1999)

PubMed=10583232; DOI=10.1046/j.1365-2141.1999.01705.x
Puthier D., Derenne S., Barille S., Moreau P., Harousseau J.-L., Bataille F.-R., Amiot M.
Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells.
Br. J. Haematol. 107:392-395(1999)

DOI=10.1007/0-306-46877-8_4
Jernberg-Wiklund H., Nilsson K.
Multiple myeloma cell lines.
(In book chapter) Human cell culture. Vol. 3. Cancer cell lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York; USA (2000)

PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2
Drexler H.G., Matsuo Y.
Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia.
Leuk. Res. 24:681-703(2000)

DOI=10.1016/B978-0-12-221970-2.50457-5
Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001)

PubMed=11154231; DOI=10.1182/blood.V97.2.516
Hjertner O., Hjorth-Hansen H., Borset M., Seidel C., Waage A., Sundan A.
Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells.
Blood 97:516-522(2001)

PubMed=11157491; DOI=10.1182/blood.V97.3.729
Chesi M., Brents L.A., Ely S.A., Bais C., Robbiani D.F., Mesri E.A., Kuehl W.M., Bergsagel P.L.
Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.
Blood 97:729-736(2001)

PubMed=11429052; DOI=10.1111/j.1349-7006.2001.tb01142.x; PMCID=PMC5926752
Hanamura I., Iida S., Akano Y., Hayami Y., Kato M., Miura K., Harada S., Banno S., Wakita A., Kiyoi H., Naoe T., Shimizu S., Sonta S.-i., Nitta M., Taniwaki M., Ueda R.
Ectopic expression of MAFB gene in human myeloma cells carrying (14;20)(q32;q11) chromosomal translocations.
Jpn. J. Cancer Res. 92:638-644(2001)

PubMed=14555701
Shammas M.A., Shmookler Reis R.J., Akiyama M., Koley H., Chauhan D., Hideshima T., Goyal R.K., Hurley L.H., Anderson K.C., Munshi N.C.
Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma.
Mol. Cancer Ther. 2:825-833(2003)

PubMed=15215163; DOI=10.1016/S0002-9440(10)63276-2; PMCID=PMC1618545
Inoue J., Otsuki T., Hirasawa A., Imoto I., Matsuo Y., Shimizu S., Taniwaki M., Inazawa J.
Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma.
Am. J. Pathol. 165:71-81(2004)

PubMed=16956823
Bataille F.-R., Jego G., Robillard N., Barille-Nion S., Harousseau J.-L., Moreau P., Amiot M., Pellat-Deceunynck C.
The phenotype of normal, reactive and malignant plasma cells Identification of 'many and multiple myelomas' and of new targets for myeloma therapy.
Haematologica 91:1234-1240(2006)

PubMed=17171682; DOI=10.1002/gcc.20404
Lombardi L., Poretti G., Mattioli M., Fabris S., Agnelli L., Bicciato S., Kwee I., Rinaldi A., Ronchetti D., Verdelli D., Lambertenghi-Deliliers G., Bertoni F., Neri A.
Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease.
Genes Chromosomes Cancer 46:226-238(2007)

PubMed=17229644; DOI=10.3324/haematol.10300
Sanda T., Iida S., Kayukawa S., Ueda R.
Induction of class II major histocompatibility complex expression in human multiple myeloma cells by retinoid.
Haematologica 92:115-120(2007)

PubMed=17692805; DOI=10.1016/j.ccr.2007.07.003; PMCID=PMC2083698
Keats J.J., Fonseca R., Chesi M., Schop R., Baker A., Chng W.-J., Van Wier S., Tiedemann R., Shi C.-X., Sebag M., Braggio E., Henry T., Zhu Y.-X., Fogle H., Price-Troska T.L., Ahmann G.J., Mancini C., Brents L.A., Kumar S.K., Greipp P.R., Dispenzieri A., Bryant B., Mulligan G., Bruhn L., Barrett M.T., Valdez R., Trent J.M., Stewart A.K., Carpten J.D., Bergsagel P.L.
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.
Cancer Cell 12:131-144(2007)

PubMed=18647998; DOI=10.1093/jncimonographs/lgn011; PMCID=PMC2737184
Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.
Characterization of MYC translocations in multiple myeloma cell lines.
J. Natl. Cancer Inst. Monogr. 39:25-31(2008)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=21173094; DOI=10.3324/haematol.2010.033456; PMCID=PMC3069235
Moreaux J., Klein B., Bataille F.-R., Descamps G., Maiga S., Hose D., Goldschmidt H., Jauch A., Reme T., Jourdan M., Amiot M., Pellat-Deceunynck C.
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines.
Haematologica 96:574-582(2011)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22806891; DOI=10.1182/blood-2011-08-371567
Holien T., Vatsveen T.K., Hella H., Waage A., Sundan A.
Addiction to c-MYC in multiple myeloma.
Blood 120:2450-2453(2012)

PubMed=23074853; DOI=10.1134/S1990519X12050136
Turilova V.I., Smirnova T.D.
Karyotypic variability of human myeloma cell lines.
Tsitologiia 54:621-636(2012)

PubMed=23992230; DOI=10.1111/ejh.12192; PMCID=PMC3834223
Greenberg A.J., Walters D.K., Kumar S.K., Rajkumar S.V., Jelinek D.F.
Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels.
Eur. J. Haematol. 91:504-513(2013)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25688540; DOI=10.1002/cyto.a.22643
Maiga S., Brosseau C., Descamps G., Dousset C., Gomez-Bougie P., Chiron D., Menoret E., Kervoelen C., Vie H., Cesbron A., Moreau-Aubry A., Amiot M., Pellat-Deceunynck C.
A simple flow cytometry-based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines.
Cytometry A 87:285-288(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

CLPUB00604
Chow S.
Targeted capture and sequencing of immunoglobulin rearrangements in multiple myeloma to enable detection of minimal residual disease.
Thesis MSc (2017); University of Toronto; Toronto; Canada

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=30285677; DOI=10.1186/s12885-018-4840-5; PMCID=PMC6167786
Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.H., Koeffler H.P.
Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.
BMC Cancer 18:940.1-940.13(2018)

PubMed=30545397; DOI=10.1186/s13045-018-0679-0; PMCID=PMC6293660
Tessoulin B., Moreau-Aubry A., Descamps G., Gomez-Bougie P., Maiga S., Gaignard A., Chiron D., Menoret E., Le Gouill S., Moreau P., Amiot M., Pellat-Deceunynck C.
Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways.
J. Hematol. Oncol. 11:137.1-137.13(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31160637; DOI=10.1038/s41598-019-44491-x; PMCID=PMC6547646
Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G.
The LL-100 panel: 100 cell lines for blood cancer studies.
Sci. Rep. 9:8218-8218(2019)

PubMed=32123307; DOI=10.1038/s41375-020-0785-1; PMCID=PMC7483300
Sarin V., Yu K., Ferguson I.D., Gugliemini O., Nix M.A., Hann B., Sirota M., Wiita A.P.
Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis.
Leukemia 34:2754-2765(2020)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) ATCC; TIB-196
BCRC; 60437
BCRJ; 0240 - Discontinued
CCTCC; GDC0301
CCTCC; GDC0325
CLS; 300259
DSMZ; ACC-9
ECACC; 85051003
IBRC; C10148
IZSLER; BS TCL 233
KCB; KCB 2013024YJ
NCBI_Iran; C151
Cell line databases/resources CLO; CLO_0009457
CLO; CLO_0009458
MCCL; MCC:0000471
CLDB; cl4584
CLDB; cl4609
cancercelllines; CVCL_0566
CCRID; 1101HUM-PUMC000684
CCRID; 4201HUM-CCTCC00325
Cell_Model_Passport; SIDM00417
CGH-DB; 37-1
CGH-DB; 9155-4
Cosmic-CLP; 753615
DepMap; ACH-000626
DSMZCellDive; ACC-9
IGRhCellID; U266B1
LINCS_LDP; LCL-2050
Lonza; 106
Lonza; 807
Anatomy/cell type resources BTO; BTO_0001594
Biological sample resources BioSample; SAMN01821605
BioSample; SAMN01821669
BioSample; SAMN03472935
BioSample; SAMN10987866
Chemistry resources ChEMBL-Cells; CHEMBL3308535
ChEMBL-Targets; CHEMBL2366315
GDSC; 753615
PharmacoDB; U266B1_1630_2019
PubChem_Cell_line; CVCL_0566
Encyclopedic resources Wikidata; Q54973634
Experimental variables resources EFO; EFO_0001254
Gene expression databases ArrayExpress; E-MTAB-38
ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
ArrayExpress; E-MTAB-7721
ArrayExpress; E-MTAB-7722
ArrayExpress; E-TABM-937
GEO; GSM143345
GEO; GSM545498
GEO; GSM545499
GEO; GSM562821
GEO; GSM827442
GEO; GSM887721
GEO; GSM888815
GEO; GSM1374970
GEO; GSM1670556
Polymorphism and mutation databases Cosmic; 720795
Cosmic; 742953
Cosmic; 753615
Cosmic; 759903
Cosmic; 759912
Cosmic; 760401
Cosmic; 760647
Cosmic; 886087
Cosmic; 888019
Cosmic; 991555
Cosmic; 1424220
Cosmic; 1483078
Cosmic; 1762463
Cosmic; 1889513
Cosmic; 2081409
Cosmic; 2159571
Cosmic; 2367281
Cosmic; 2391806
Cosmic; 2809754
IARC_TP53; 361
IARC_TP53; 30185
LiGeA; CCLE_465
Progenetix; CVCL_0566
Proteomic databases PRIDE; PXD030304
Sequence databases EGA; EGAS00001000610
EGA; EGAS00001000978
EGA; EGAS00001002554
Entry history
Entry creation04-Apr-2012
Last entry update19-Dec-2024
Version number46